PI3K (class I isoforms) and mTORC1/mTORC2

Class

pan-PI3K and dual mTORC1/mTORC2 small-molecule inhibitor; potent against all four class I PI3K isoforms (alpha, beta, gamma, delta) and both mTOR complexes, differentiating it from agents that target only PI3Kalpha, AKT, or mTORC1

Pathway

blocks PI3K/AKT/mTOR signaling both upstream and downstream of AKT via combined PI3K and mTORC1/mTORC2 inhibition, giving broader pathway suppression than isoform-selective PI3K or mTORC1-only inhibitors and intended to circumvent resistance mechanisms

The PI3K/AKT/mTOR pathway is one of the principal intracellular signaling routes that cells use to translate growth-factor and nutrient signals into decisions about growth, survival, and metabolism. Phosphoinositide 3-kinases (PI3K) exist as four related class I isoforms (alpha, beta, gamma, delta), each activated by different upstream receptors, and they in turn activate AKT, which feeds into mTOR, a kinase that exists in two distinct complexes, mTORC1 and mTORC2. In many cancers, mutations or amplifications at multiple points along this cascade keep it persistently active, driving uncontrolled proliferation and resistance to cell death. A therapy that inhibits only one isoform of PI3K, or only AKT, or only mTORC1, can be circumvented because the tumor reactivates signaling through a parallel node in the same network. The mechanism described here blocks all four class I PI3K isoforms together with both mTOR complexes, producing broader and more durable suppression of the pathway at multiple levels simultaneously, upstream and downstream of AKT. This comprehensive blockade is intended to close off the redundant routes tumors use to escape narrower inhibition, at the cost of affecting normal tissues that rely on the same pathway for metabolic regulation and immune function. This mechanism is broadly relevant to solid tumors and hematologic malignancies in which PI3K/AKT/mTOR signaling is dysregulated.